TAK-003 is currently undergoing regulatory review for potential licensure in both the European Union
Operations at Oakville, Canada manufacturing plant expected to end by first quarter 2023
The company has posted net loss of Rs. 67.65 crores for the Financial Year ended March 31, 2022
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The company has posted net profit of Rs.605.05 crores for the Financial Year ended March 31, 2022
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Cipla has reported consolidated financial results for the period ended March 31, 2022
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Subscribe To Our Newsletter & Stay Updated
